Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 96,742 shares at $3.70 ($358K) on 2021-12-09, disclosed to the SEC on 2021-12-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.70 | 43,108 | $159K | 44.5% |
| 2 | $3.70 | 43,108 | $160K | 44.5% |
| 3 | $3.75 | 10,526 | $39K | 11.0% |
| Total | $3.71 avg | 96,742 | $358K | 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2020-05-04 | $784K | — | Filing → |